Imagion Biosystems Advances Phase 1b/2 Trial with CRO Agreements and Product Ready

Clinical Trial Milestones Accelerate

Imagion Biosystems (ASX:IBX) has taken a major step forward in its quest to revolutionise cancer imaging with the MagSense HER2 Imaging Agent. The company has executed work orders with its primary contract research organisation (CRO) and specialist CROs handling imaging and pathology for its Phase 1b/2 clinical trial. This solidifies the operational foundation needed to progress towards trial start-up, including site selection, data management, and investigator training.

Manufacturing of the MagSense investigational product (IP) is complete, with the agent passing stability tests and ready for distribution to clinical sites. This ensures the trial can proceed without delays once patient enrolment begins, a critical factor in maintaining momentum after the recent FDA clearance to proceed with the study.

Trial Site Engagement and Protocol Finalisation

The company is actively advancing trial initiation activities with seven prospective sites, having received confirmed intent to participate from the first US clinical team and now negotiating contracts. This progress is crucial given the complexity of clinical trial logistics and regulatory compliance, especially in a multi-site study.

Imagion has finalised its imaging protocol, incorporating advanced quantitative MRI techniques developed through prior collaborations with Wayne State University and Siemens Healthineers. These enhancements aim to improve the diagnostic precision of the MagSense agent beyond conventional imaging methods.

Significance of the MagSense HER2 Imaging Agent Trial

HER2-positive breast cancer affects approximately 450,000 women globally each year and is associated with aggressive disease and high recurrence risk. Accurate nodal staging is vital for tailoring treatment but current imaging methods like ultrasound have limitations in sensitivity and specificity.

The MagSense HER2 Imaging Agent, a molecular MRI technology that uses targeted magnetic nanoparticles without radiation, demonstrated promising results in the Phase 1 trial by clearly differentiating tumour-involved lymph nodes. The Phase 1b/2 trial will optimise dosing and imaging timing while assessing diagnostic performance. Success here could address a critical unmet need for more precise, non-invasive cancer detection.

Trial Design and Expected Outcomes

The trial is structured in three parts: initial safety data collection (Part A), evaluation of reduced dosing and imaging protocol (Part B), and a larger cohort to establish diagnostic performance (Part C). Completion is anticipated within 18 to 24 months, with interim analyses planned after Parts A and B.

Beyond diagnostic metrics, the study aims to provide insights into cost of care, patient outcomes, and clinical value. The integration of quantitative imaging also sets the stage for developing AI diagnostic tools, potentially boosting future clinical applications.

Leadership and Technology Outlook

Dr Eghtedari, Section Chief of Women’s Imaging at City of Hope hospital in Los Angeles, will serve as principal investigator. His prior involvement as an independent reviewer of the Phase 1 study adds continuity and expertise to the trial’s leadership.

Imagion’s MagSense technology represents a novel class of MRI imaging agents that enhance cancer detection without ionising radiation. The company is also exploring applications beyond breast cancer, with agents identified for prostate and ovarian cancers, positioning it for broader clinical impact as resources allow.